1.14
price up icon1.79%   0.02
after-market 시간 외 거래: 1.15 0.01 +0.88%
loading
전일 마감가:
$1.12
열려 있는:
$1.14
하루 거래량:
1.51M
Relative Volume:
0.76
시가총액:
$191.44M
수익:
$13.45M
순이익/손실:
$-178.23M
주가수익비율:
-0.6909
EPS:
-1.65
순현금흐름:
$-132.53M
1주 성능:
-2.56%
1개월 성능:
-5.79%
6개월 성능:
-30.91%
1년 성능:
-65.03%
1일 변동 폭
Value
$1.10
$1.20
1주일 범위
Value
$1.025
$1.20
52주 변동 폭
Value
$0.6611
$5.92

Fate Therapeutics Inc Stock (FATE) Company Profile

Name
명칭
Fate Therapeutics Inc
Name
전화
858.875.1803
Name
주소
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Name
직원
181
Name
트위터
@fatethx
Name
다음 수익 날짜
2025-05-02
Name
최신 SEC 제출 서류
Name
FATE's Discussions on Twitter

FATE을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
FATE
Fate Therapeutics Inc
1.14 191.44M 13.45M -178.23M -132.53M -1.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-11-18 업그레이드 BofA Securities Underperform → Neutral
2024-06-17 업그레이드 Piper Sandler Neutral → Overweight
2023-03-27 재개 Wells Fargo Equal Weight
2023-01-24 다운그레이드 H.C. Wainwright Buy → Neutral
2023-01-06 다운그레이드 BMO Capital Markets Outperform → Market Perform
2023-01-06 다운그레이드 BofA Securities Buy → Underperform
2023-01-06 다운그레이드 Cowen Outperform → Market Perform
2023-01-06 다운그레이드 Piper Sandler Overweight → Neutral
2023-01-06 다운그레이드 Stifel Buy → Hold
2023-01-06 다운그레이드 Truist Buy → Hold
2023-01-06 다운그레이드 Wedbush Outperform → Neutral
2023-01-03 다운그레이드 Guggenheim Buy → Neutral
2022-12-22 다운그레이드 Oppenheimer Outperform → Perform
2022-12-15 개시 Goldman Sell
2022-11-04 재개 Cantor Fitzgerald Overweight
2022-10-10 개시 Canaccord Genuity Buy
2022-08-18 재개 Wells Fargo Overweight
2022-07-28 개시 Needham Hold
2022-07-11 업그레이드 BMO Capital Markets Market Perform → Outperform
2022-06-03 개시 Robert W. Baird Neutral
2022-02-11 재개 BMO Capital Markets Market Perform
2021-12-15 업그레이드 Wedbush Neutral → Outperform
2021-12-07 개시 Cowen Outperform
2021-11-09 업그레이드 Citigroup Neutral → Buy
2021-08-26 개시 Morgan Stanley Equal-Weight
2021-06-07 업그레이드 H.C. Wainwright Neutral → Buy
2021-05-07 업그레이드 Wedbush Neutral → Outperform
2021-04-26 재개 Jefferies Buy
2021-02-26 개시 BofA Securities Buy
2021-02-26 다운그레이드 Wedbush Outperform → Neutral
2021-02-11 다운그레이드 Citigroup Buy → Neutral
2021-01-27 재개 H.C. Wainwright Neutral
2020-05-13 개시 H.C. Wainwright Buy
2020-03-04 개시 Barclays Overweight
2020-01-09 다운그레이드 BMO Capital Markets Outperform → Market Perform
2019-12-30 재확인 Mizuho Buy
2019-12-09 업그레이드 Wells Fargo Market Perform → Outperform
2019-11-12 개시 SunTrust Buy
2019-11-06 다운그레이드 Wells Fargo Outperform → Market Perform
2019-10-01 개시 Stifel Buy
2019-08-09 개시 BTIG Research Buy
2019-07-22 개시 Cantor Fitzgerald Overweight
2019-07-12 개시 Oppenheimer Outperform
2019-06-13 개시 Mizuho Buy
2019-06-07 개시 ROTH Capital Neutral
2019-05-31 개시 Guggenheim Buy
2019-05-24 재개 Citigroup Buy
2019-03-28 개시 SVB Leerink Outperform
2019-01-03 다운그레이드 Stephens Overweight → Equal-Weight
2018-11-05 개시 Jefferies Buy
2018-08-01 개시 Citigroup Buy
2018-03-06 다운그레이드 H.C. Wainwright Buy → Neutral
모두보기

Fate Therapeutics Inc 주식(FATE)의 최신 뉴스

pulisher
Jun 15, 2025

Institutional owners may take dramatic actions as Fate Therapeutics, Inc.'s (NASDAQ:FATE) recent 20% drop adds to one-year losses - simplywall.st

Jun 15, 2025
pulisher
Jun 14, 2025

Fate Therapeutics’ SWOT analysis: promising data boosts stock outlook - Investing.com

Jun 14, 2025
pulisher
Jun 14, 2025

TC Biopharm (NASDAQ:TCBP) versus Fate Therapeutics (NASDAQ:FATE) Critical Review - Defense World

Jun 14, 2025
pulisher
Jun 13, 2025

Fate Therapeutics (NASDAQ:FATE) Given “Hold” Rating at Needham & Company LLC - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

FATE: Analyst Maintains Hold Rating on Fate Therapeutics | FATE Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Needham maintains hold on Fate Therapeutics stock despite lupus data By Investing.com - Investing.com Canada

Jun 12, 2025
pulisher
Jun 12, 2025

Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report? - Yahoo Finance

Jun 12, 2025
pulisher
Jun 11, 2025

Fate Therapeutics price target lowered to $2.20 by BofA on SLE data - Investing.com Canada

Jun 11, 2025
pulisher
Jun 11, 2025

Fate Therapeutics (FATE) Shares Promising Data on FT819 for Lupus Treatment | FATE Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress - The Manila Times

Jun 11, 2025
pulisher
Jun 11, 2025

Fate Therapeutics Reports Promising Clinical Data for FT819 in Treating Severe Lupus Nephritis at EULAR 2025 - Nasdaq

Jun 11, 2025
pulisher
Jun 11, 2025

Fate’s FT819 shows promising results in lupus patients - Investing.com

Jun 11, 2025
pulisher
Jun 11, 2025

Breakthrough: Fate's Off-the-Shelf CAR T-Cell Shows 100% Response Rate in Severe Lupus Patients - Stock Titan

Jun 11, 2025
pulisher
Jun 11, 2025

Squarepoint Ops LLC Purchases 20,805 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Bank of America Corp DE Sells 550,066 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Comments on FATE FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Top Cancer Stocks to Supercharge Your 2025 Portfolio - Yahoo Finance

Jun 10, 2025
pulisher
Jun 10, 2025

Two Sigma Investments LP Cuts Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jun 10, 2025
pulisher
Jun 10, 2025

Jane Street Group LLC Has $51,000 Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jun 10, 2025
pulisher
Jun 08, 2025

Millennium Management LLC Increases Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

Ameriprise Financial Inc. Sells 72,581 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Public Employees Retirement System of Ohio Sells 46,100 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Fate Therapeutics Inc (NASDAQ:FATE) Price Forecast For The Next 12 Months Is Set At 3. - Marketing Sentinel

Jun 05, 2025
pulisher
Jun 04, 2025

ProShare Advisors LLC Has $56,000 Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic - MSN

Jun 03, 2025
pulisher
May 31, 2025

Fate Therapeutics appoints new board member By Investing.com - Investing.com South Africa

May 31, 2025
pulisher
May 30, 2025

Fate Therapeutics Appoints Matthew Abernethy to Board of Directors, Timothy P. Coughlin Steps Down - Nasdaq

May 30, 2025
pulisher
May 30, 2025

Fate Therapeutics appoints new board member - Investing.com

May 30, 2025
pulisher
May 30, 2025

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors - GlobeNewswire

May 30, 2025
pulisher
May 30, 2025

Fate Therapeutics Approves Key Proposals at Annual Meeting - TipRanks

May 30, 2025
pulisher
May 29, 2025

Fate Therapeutics to present lupus treatment data at EULAR 2025 By Investing.com - Investing.com South Africa

May 29, 2025
pulisher
May 29, 2025

Fate Therapeutics to present lupus treatment data at EULAR 2025 - Investing.com Australia

May 29, 2025
pulisher
May 28, 2025

Fate Therapeutics, Inc. (FATE) Highlights Next-Gen iPSC Therapies for Autoimmune Diseases - Insider Monkey

May 28, 2025
pulisher
May 28, 2025

Prime Mining: Expanding a High-Grade Gold and Silver Resource in Mexico - The Globe and Mail

May 28, 2025
pulisher
May 28, 2025

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress - The Manila Times

May 28, 2025
pulisher
May 28, 2025

Viridian Metals: Targeting Critical Copper Discoveries in Newfoundland - The Globe and Mail

May 28, 2025
pulisher
May 28, 2025

Fate Therapeutics Announces Phase 1 Data Presentation of - GlobeNewswire

May 28, 2025
pulisher
May 28, 2025

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress - GlobeNewswire Inc.

May 28, 2025
pulisher
May 28, 2025

Northern Trust Corp Cuts Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

May 28, 2025
pulisher
May 27, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of “Hold” by Analysts - Defense World

May 27, 2025
pulisher
May 26, 2025

Fate Therapeutics’ SWOT analysis: stock outlook amid clinical progress By Investing.com - Investing.com Canada

May 26, 2025
pulisher
May 26, 2025

Fate Therapeutics’ SWOT analysis: stock outlook amid clinical progress - Investing.com

May 26, 2025
pulisher
May 25, 2025

BNP Paribas Financial Markets Raises Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

May 25, 2025
pulisher
May 23, 2025

Fate Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 23, 2025
pulisher
May 19, 2025

Price T Rowe Associates Inc. MD Cuts Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

May 19, 2025
pulisher
May 17, 2025

StockNews.com Upgrades Fate Therapeutics (NASDAQ:FATE) to Hold - Defense World

May 17, 2025
pulisher
May 17, 2025

Barclays Cuts Fate Therapeutics (NASDAQ:FATE) Price Target to $2.00 - Defense World

May 17, 2025
pulisher
May 17, 2025

Wedbush Predicts Increased Earnings for Fate Therapeutics - Defense World

May 17, 2025
pulisher
May 17, 2025

What is Leerink Partnrs’ Estimate for FATE Q2 Earnings? - Defense World

May 17, 2025
pulisher
May 16, 2025

Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus - MSN

May 16, 2025
pulisher
May 16, 2025

Needham & Company LLC Reiterates “Hold” Rating for Fate Therapeutics (NASDAQ:FATE) - Defense World

May 16, 2025

Fate Therapeutics Inc (FATE) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Fate Therapeutics Inc 주식 (FATE) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Bressi Jerome Charles
See Remarks
Jan 10 '25
Sale
1.55
5,980
9,269
270,203
TAHL CINDY
See Remarks
Jan 10 '25
Sale
1.55
5,654
8,764
336,707
Valamehr Bahram
President and CEO
Jan 10 '25
Sale
1.54
8,705
13,406
349,364
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
자본화:     |  볼륨(24시간):